FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive he

March 26, 2026
- Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures, supporting treatment [2]
- DeviceGuide integrates with Philips Azurion image-guided therapy platform that combines imaging, real-time data and intelligent software within a unified workflow to support more consistent, efficient and confidently guided minimally invasive procedures
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-powered software solution that assists physicians during one of interventional cardiology’s most technically demanding procedures – repairing leaking mitral valves through a minimally invasive approach.
DeviceGuide was developed in close collaboration with Edwards Lifesciences, the global leader in structural heart innovation, aligning Philips’ imaging and AI expertise with Edwards’ expertise in valvular heart therapy development. Together, the companies have innovated image guidance of the mitral transcatheter edge-to-edge repair (M-TEER) workflow to make these complex minimally invasive heart valve repair procedures more intuitive and streamlined.

Physician using DeviceGuide with EchoNavigator 5
DeviceGuide will be showcased at the American College of Cardiology (ACC) 2026 meeting in New Orleans, one of the world’s leading forums for cardiovascular innovation.
Transforming treatment for a common heart condition
A leaking mitral valve, known as mitral regurgitation (MR), affects more than 35 million adults worldwide and over 2 million in the U.S. [3, 4]. Minimally invasive transcatheter techniques such as M-TEER offer an alternative to open heart surgery in selective patient populations.

Philips DeviceGuide with EchoNavigator 5 Screen
During M-TEER procedures, physicians make a small skin incision to access a vein which allows the introduction of a catheter to the heart to deliver a repair device to the diseased mitral valve. Because the mitral valve is inherently a complex and heterogeneous structure, transcatheter repair of the valve requires experienced physicians positioning the device delivery system, and physicians guiding the placement of the device. In guiding and positioning the repair device, the intraprocedural heart team must interpret both X-ray and ultrasound images on multiple screens, communicate and coordinate movements between two operators, and make precise adjustments to grasp the moving valve leaflets and then confirm the result in real time. The process demands accuracy, coordination, and experience from the entire team – and this is where DeviceGuide can help with navigation guidance.

DeviceGuide with EchoNavigator 5
How AI assists inside the beating heart
Built on Philips’ EchoNavigator echo-fluoro fusion technology, which combines live echocardiography images from Philips EPIQ CVxi cardiovascular platform with live X-ray images from Philips Azurion image-guided therapy system, DeviceGuide brings real-time AI guidance directly into the procedure room.
The software’s AI algorithm automatically tracks and visualizes the Edwards PASCAL Ace mitral valve repair device, combining live ultrasound and X-ray images into a single, integrated view. This helps clinicians navigate and position the device with greater clarity and confidence.
“The AI software serves as an assistive tool; the physician always remains in control. This isn’t about replacing expertise – it’s about amplifying it,” explains Dr. Atul Gupta, Chief Medical Officer Diagnosis & Treatment at Philips. “By embedding AI into the procedure, DeviceGuide gives physicians an extra pair of eyes, helping them treat more patients safely and confidently.”
Collaboration with clinical partners
In developing DeviceGuide, Philips and Edwards worked closely with investigational sites in Europe and the U.S., including a team at the Structural Heart and Valve Center at NewYork-Presbyterian/Columbia University Irving Medical Center, led by interventional cardiologist Susheel Kumar Kodali, MD, director, and Rebecca T. Hahn, MD, director of interventional echocardiography.
“In helping to guide mitral repair procedures, one of my roles as an echocardiographer is to help the interventional cardiologist understand the complex anatomy of the valve which will determine the orientation, trajectory and position of the repair device relative to the target and the surrounding structures,” said Dr. Hahn. “Since AI auto-aligns imaging to the device in real time and continuously informs the interventionalist about the location of the device in space on the imaging screen, it minimizes unnecessary repositioning of the imaging window, streamlines procedural guidance and may improve the precision of device implantation.”
“DeviceGuide provides me with a visual overlay, trajectory line and orientation line of the therapy device in both live 3D echo and fluoroscopic images during mitral valve repair procedures,” said Dr. Kodali. “Having a single, intuitive presentation of real-time target, orientation and auto device-aligned views simplifies this procedure and improves team communication.”
Supporting teams in real time
“Structural heart procedures are among the fastest-growing areas in cardiology, and also among the most complex,” said Mark Stoffels, Business Leader, Image Guided Therapy Systems at Philips. “By assisting physicians with real-time visualization and navigation inside the beating heart, DeviceGuide helps them manage that complexity, and perform procedures more confidently, with the ultimate goal to treat more patients effectively. It fits seamlessly into cath-lab workflows and gives the entire team a shared view of the procedure, improving coordination and confidence.”
Part of Philips’ connected cardiology ecosystem
DeviceGuide extends Philips’ connected cardiology portfolio that helps physicians care for heart patients from diagnosis through recovery. It also represents a step toward Philips’ vision of the AI-powered cath lab of the future where imaging, devices, and real-time data are intelligently connected to reduce procedural complexity and improve consistency. In hospitals, Philips systems already bring together ultrasound, X-ray, and real-time data into a unified workflow to guide minimally invasive procedures. Building on this foundation, intelligent software solutions such as DeviceGuide help care teams navigate complex structural heart interventions with greater clarity and coordination, serving as an assistive “copilot” in the procedure room.
After treatment, Philips connected monitoring tools extend care beyond the cath lab, helping care teams detect complications early and support recovery. Together, these innovations create a connected cardiology ecosystem that helps care teams diagnose earlier, treat less invasively, improve procedural efficiency, and support recovery – improving outcomes and experiences for heart patients everywhere.
Availability
DeviceGuide enabled by EchoNavigator is FDA 510(k) cleared in the United States. Commercial availability is subject to market release and applicable regulatory requirements. DeviceGuide is currently intended for use with the Edwards PASCAL Ace Mitral Valve Repair System. Availability outside the U.S. varies by country and regulatory status.
A recent first-in-human publication in JACC: Case Reports describes early clinical experience using DeviceGuide for AI-supported imaging guidance during mitral transcatheter edge-to-edge repair procedures.
Read more on how Philips DeviceGuide works here.
Philips DeviceGuide enabled by EchoNavigator R5 is not available for sale or use in all countries. Its availability is subject to local regulatory clearance and market release. Please contact your Philips representative for details on product availability in your region.
Dr. Hahn reports Institutional funding to Columbia University and/or the Cardiovascular Research Foundation from Philips North America LLC, and from Edwards Lifesciences Corporation.
Dr. Kodali discloses consulting payments from Philips North America LLC and reports Institutional funding to Columbia University and/or the Cardiovascular Research Foundation from Edwards Lifesciences Corporation.
REFERENCES:
[1] DeviceGuide is currently intended for use only with the Mitral TEER Therapy Device (Edwards PASCAL Ace);
Hahn RT, Biaggi P, Corti R et al. Mitral Transcatheter Edge-to-Edge Repair Using Novel Augmented Imaging Software. JACC: Case Reports 2025;30:106160.
[2] DeviceGuide assists physicians in visualizing and navigating the repair device within the heart. It supports, but does not perform, the therapeutic procedure itself;
Biaggi P, Corti R, Gaemperli O et al. Artificial intelligence based fusion imaging streamlining mitral transcatheter edge-to-edge repair. European Heart Journal - Imaging Methods and Practice 2026;4.
[3] MDPI
[4] CDC
For further information, please contact:
Joost Maltha
Philips Global External Relations
Tel.: +31 6 1055816
E-mail: joost.maltha@philips.com
Avi Dines
Philips North America
Tel: +1 781 690 3814
E-mail: avi.dines@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- 《中西学说通辨》:跨越时空的学术对话与思想碰撞
- Microba取得炎症性肠病领域里程碑式成果并与大型肠胃科机构签约合作
- 丰尚公司参加2024中国农业国际经贸合作会议
- MCNEX持续深化区域覆盖,盐城等城市将迎新一期特训营
- Starr宣布完成对IQUW Group的收购
- Andersen在六大洲推出全球咨询业务,推动企业转型
- Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025
- 美中爱瑞第二届肿瘤临床学术年会圆满落幕,共绘肿瘤治疗未来新蓝图!
- 排卵障碍怎么办?宁波送子鸟医院为您解答
- 廿一征程 碳索未来—2025德堡共赴新机 创富共赢财富峰会隆重举行
- 科技兴农结硕果 青农优品聚人气 ——沈阳农业大学“青年农民上大学”学员亮相银杏节展销
- Forest Stewardship Council通过最新解决方案简化EUDR合规之旅
- 安仁县农发行:深入乡村守护村民“钱袋子”
- 克洛托光电闪耀长春国际光电博览会,以创新技术赋能光学产业发展
- Rimini Street Announces the Extension of Support for All SAP ECC 6.0 and S/4HANA Releases Through 20
- 鸿星尔克官宣“霸屏”全球,为泉州打call
- Snail Games 宣布参与 2025 年 Steam 秋季特卖,降低《方舟:生存飞升》、《贝尔莱特》及独立游戏组合入手门槛
- 谢卓琴《我的母亲》 一一第十届“母亲节”海内外征稿“一等奖”作品
- 中国企业加速出海步伐,尼尔森IQ研讨会揭示欧洲及亚太市场新机遇
- 企业产品双获奖!达因药业荣膺“2024米思会”两大重磅奖项
- 呼吸道传染病(新冠、流感)混合高发,该如何选药?
- 南京JLC「心动骥跃」新春盛典启幕 于城市社交客厅 演绎当代金陵年仪
- 药店如何转型?从汤头大药房到汤头泡餐饮,用汤头App,药房变厨房
- 一年一度的亚洲海工盛会将启 CM2026北京海工展聚焦智慧海洋与绿色转型
- 桑庆德|喜迎中秋献礼国庆——书画名家专题报道
- 新时代国医大师李德深中医全科院士
- 全球科创精英集结号!2025 年香港大学国际科创大赛报名已进入最后 1 天倒计时!
- 国泰海通成功发行非银金融机构首单上海自贸离岸债
- Boomi的独立研究认为云支出浪费与盲目的成本管理策略有关
- New Milestone: NIRI and Taiwan's TIRI Advance Global IR Standards
推荐
-
奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态!
2月20日凌晨2点,奥运冠军刘翔更新社交账号晒
资讯
-
男子“机闹”后航班取消,同机旅客准备集体起诉
1月4日,一男子大闹飞机致航班取消的新闻登上
资讯
-
一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷
星标★
来源:桌子的生活观(ID:zzdshg)
没
资讯
-
大家一起关注新疆乌什7.1级地震救援见闻
看到热气腾腾的抓饭马上就要出锅、村里大家
资讯
-
国足13次出战亚洲杯首次小组赛0进球
北京时间1月23日消息,2023亚洲杯小组
资讯
-
中央气象台连发四则气象灾害预警
暴雪橙色预警+冰冻橙色预警+大雾黄色预警+
资讯
-
王自如被强制执行3383万
据中国执行信息公开网消息,近期,王自如新增一
资讯
-
新增供热能力3200万平方米 新疆最大热电联产项目开工
昨天(26日),新疆最大的热电联产项目—&md
资讯
-
透过数据看城乡居民医保“含金量” 缴费标准是否合理?
记者从国家医保局了解到,近期,全国大部分地区
资讯
-
海南大学生返校机票贵 有什么好的解决办法吗?
近日,有网友在“人民网领导留言板&rdqu
资讯

